Whooping Cough Deaths Rise in U.S. as Surge in Infections Continues

As of Dec. 20 the U.S. has recorded 27,871 diagnosed pertussis (whooping cough) cases year-to-date versus 41,922 at the same point last year, remaining above typical pre-pandemic annual levels (10,000–20,000) and with at least 13 deaths reported so far compared with 10 last year. Public-health experts attribute sustained elevated transmission to declining vaccination coverage—only 79% of children born in 2021 had received four DTaP doses by age two—an issue that could sustain demand for pediatric vaccination programs and related healthcare services.

Analysis

Market structure: The immediate winners are incumbent vaccine manufacturers and public-health-facing diagnostics/CDMOs — specifically GSK (GSK), Sanofi (SNY), Merck (MRK) and diagnostic supplier Becton Dickinson (BDX) — because a sustained above‑prepandemic pertussis baseline implies recurring catch‑up vaccination and increased testing. Losers are smaller mono‑product vaccine biotechs and pediatric clinics facing surges in seasonal demand without pricing power; governments will remain the marginal buyer, limiting unit price upside but increasing volume. With US birth cohorts ~3.7M and DTaP four‑dose coverage at 79% for 2021, the underimmunized pool (~750k children) plus adult booster gaps imply material incremental annual dose demand in the low‑to‑mid hundreds of thousands.

Risk assessment: Tail risks include rapid escalation to broader respiratory co‑epidemics raising hospitalizations (days–weeks), regulatory price controls or bulk procurement that compresses margins (months), and production bottlenecks for adjuvants/CMOs (quarters). Immediate effects: higher antibiotic scripts and diagnostic volumes; short term (3–6 months): government procurement/awareness campaigns; long term (12–36 months): structural lower vaccine adherence could either sustain demand or invite substitution/innovation. Key hidden dependencies are ACIP/CDC guidance, state school‑entry mandates, and cold‑chain capacity; catalysts include CDC weekly case updates and upcoming ACIP votes.

Trade implications: Tactical trades: establish modest long positions in GSK (2–3% NAV) and SNY (1–2% NAV) to capture procurement and adult‑booster demand, and a 1% long in BDX to play testing volume; prefer 3–9 month call spreads (10–20% OTM) to limit capital and time risk. Pair trade: long GSK vs short MRNA (1:1) to express durable vaccine demand vs speculative mRNA vaccine rerating risk. Entry within 30 days; trim on positive ACIP guidance or a 15–25% move.

Contrarian angles: The market underestimates the size of repeat adult booster demand — small per‑dose revenue can scale via government contracts — but may overestimate margin upside because price negotiation is likely; prefer diversified vaccine franchises over single‑asset biotechs. Historical pertussis cycles (2012 spike) show recurring peaks rather than sustained runaway outbreaks, so avoid overlevered long duration bets; unintended consequences include increased regulatory scrutiny and accelerated competing combination vaccines that could re‑rate incumbents negatively over 2–4 years.

Key Decisions for Investors

• Establish a 2–3% NAV long position in GSK (ticker: GSK) via a 6–9 month call spread (buy 10–15% ITM call, sell 25% OTM call) to capture near‑term booster/procurement demand; exit/trim on ACIP endorsement or a 20% price move.
• Initiate a 1–2% NAV long position in Sanofi (ticker: SNY) cash equity; add if CDC weekly pertussis case counts rise >20% month‑over‑month or if state bulk‑purchase announcements occur within 60 days.
• Buy a 1% NAV long in BDX (Becton Dickinson) via 3–6 month calls to play diagnostic volume upside; target a double if testing volumes rise 15%+ versus prior quarter; stop‑loss at 30% downside.
• Implement a pair trade: long GSK (size A) and short Moderna (MRNA, size A) to hedge biotech valuation risk; rebalance if GSK outperforms MRNA by >12% in 90 days or on major ACIP/CMS procurement news.
• Avoid concentrated longs in small vaccine biotechs; reduce exposure >50% if a state/federal price‑control bill targeting vaccine procurement passes or if supplier‑side alerts (CMO shortages) are reported within 90 days.